DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effect of Colchicine for the Palliative Management of Hepatocellular Carcinoma

Information source: Kaohsiung Medical University Chung-Ho Memorial Hospital
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hepatocellular Carcinoma; Metastasis; Invasion

Intervention: Colchicine (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: Kaohsiung Medical University Chung-Ho Memorial Hospital

Official(s) and/or principal investigator(s):
Zu Y Lin, MS, Principal Investigator, Affiliation: Kaohsiung Medical University

Overall contact:
Zu Y Lin, MS, Phone: 886-7-323-4553, Email: linzuyau@yahoo.com.tw

Summary

This trial is to evaluate the potential of colchicine for the palliative management of hepatocellular carcinoma patients with distant metastasis or large vessel invasion using the Department of Health R. O.C. approved doses and methods of administration.

Clinical Details

Official title: Evaluation the Potential of Colchicine for the Palliative Management of Hepatocellular Carcinoma Patients With Distant Metastasis or Large Vessel Invasion

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: overall survival

Secondary outcome: Number of participants with adverse events

Eligibility

Minimum age: 20 Years. Maximum age: 90 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. . Patient has at least one of the following criteria: (1) positive for hepatocellular carcinoma evidenced by cytology or pathology, (2) serum alpha-fetoprotein level > 400 ng/mL and has evidence of hepatocellular carcinoma provided by contrast-enhanced computed tomography or magnetic resonance imaging. 2. . Contrast-enhanced computed tomography or magnetic resonance imaging has evidence of distant metastasis or large vessel invasion caused by hepatocellular carcinoma. 3. . Patient has Child A hepatic reserved function Exclusion Criteria: 1. . There are life-threatening hemorrhage including gastrointestinal hemorrhage and hemorrhage from other vital organs such as lungs or brain. 2. . There are life-threatening bacterial, fungal or viral infection (not included hepatitis B and C virus). 3. . Patient has serum creatinine level > 1. 5 mg/dL. 4. . Patient must receive long-term medication of statin or fibrates drugs and these medications can not be changed. 5. . Patient has white blood cell count < 1500/µL, platelet count < 30000/µL or hemoglobin < 9. 0 gm/dL after medication. 6. . Pregnant woman or plan to be a pregnant woman 7. . allergy to colchicine or has history of severe side effects caused by colchicine 8. . Patient has received systemic chemotherapy within 2 months before enrollment or plans to receive systemic chemotherapy in the future. 9. . Patient is under or plans to receive Nexavar or other clinical trial testing drug. 10. . Patient has severe malfunction of vital organs and can not participate in this study justified by the doctor in this research team. 11. . Patient is under or plans to receive Chinese traditional medicine or herb drugs.

Locations and Contacts

Zu Y Lin, MS, Phone: 886-7-323-4553, Email: linzuyau@yahoo.com.tw

Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan; Recruiting
Z Y Lin, MS, Phone: 886-7-323-4553, Email: linzuyau@yahoo.com.tw
Zu Y Lin, MS, Principal Investigator
W L Chuang, PhD, Sub-Investigator
M L Yu, PhD, Sub-Investigator
S C Chen, PhD, Sub-Investigator
C Y Dai, PhD, Sub-Investigator
M L Yeh, MD, Sub-Investigator
J F Huang, PhD, Sub-Investigator
M Y Hsieh, MS, Sub-Investigator
Additional Information

Related publications:

Lin ZY, Wu CC, Chuang YH, Chuang WL. Anti-cancer mechanisms of clinically acceptable colchicine concentrations on hepatocellular carcinoma. Life Sci. 2013 Sep 3;93(8):323-8. doi: 10.1016/j.lfs.2013.07.002. Epub 2013 Jul 16.

Starting date: August 2013
Last updated: May 19, 2015

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017